OMass Therapeutics: The 21st Century Vertex?

Published

April 29, 2022

OMass Therapeutics: The 21st Century Vertex?

Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive
$100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform, which is based on mass spectrometry, could open the door to an innovative approach to drug discovery…

MORERelated News
Biotech Review of the Year
The main challenge in 2023 was that global economic conditions (war in Ukraine, war in the Middle East, increasing interest...
The Life Sciences Sector Successfully Toughs Out Economic Challenges
Miguel Silva, Strategy Director at OMass Therapeutics which spun out of the University of Oxford. The company uses novel biochemistry...
Scrip Asks…What Does 2024 Hold For Biopharma? Part 1: Business Strategy And Leadership
Ros Deegan, CEO at OMass Therapeutics, Ltd, which develops new treatments using novel mass spectrometry approaches, also urged boldness (as well...